The learning objectives of this program are:
- Review the regulatory requirements for agents that are approved as biosimilars for reference biologic agents
- Evaluate clinical evidence for biosimilars compared with reference biologic agents as treatment for retinal diseases
- Develop strategies to address concerns regarding the use of biosimilars in patients with retinal diseases
Learning Objectives
Upon completion of this activity, participants will be able to:
- Discuss the role of inflammation in the pathogenesis of diabetic macular edema
- Identify limitations associated with current management and treatment strategies for diabetic macular edema
- Implement evidence-based therapies for patients who fail or exhibit a suboptimal response to conventional treatment for diabetic macular edema